Skip to main content
Jon Cuthbert Profile pIcture
Jon Cuthbert

Jon Cuthbert

GrafaFounder & COO

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.

Articles by Jon Cuthbert

Grafa

Adagene masked CTLA-4 shows breakthrough potential in colorectal cancer

Adagene (NASDAQ:ADAG) reported updated clinical data for its lead "SAFEbody" candidate, muzastotug, revealing a significant dose-dependent response in patients with treatment-resistant colorectal cancer—a population that has traditionally been unresponsive to immunotherapy.

Read more: Adagene masked CTLA-4 shows breakthrough potential in colorectal cancer
Grafa
Health

Immunovant shares tumble as batoclimab fails primary endpoint in pair of Phase 3 TED studies

Immunovant (NASDAQ:IMVT) announced topline results from two Phase 3 clinical studies evaluating batoclimab in patients with active, moderate-to-severe thyroid eye disease (TED) on Thursday, April 2, 2026.

Read more: Immunovant shares tumble as batoclimab fails primary endpoint in pair of Phase 3 TED studies